New TB vaccines enter human trials – could they beat the world’s deadliest infection?
NCT ID NCT05547464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental vaccines (BNT164a1 and BNT164b1) to see if they are safe and trigger an immune response against tuberculosis. About 500 healthy adults who have already received the BCG vaccine will receive three doses of either a vaccine or a placebo. The goal is to find the best dose for future larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Africa Health Research Institute (AHRI)
Mtubatuba, 3935, South Africa
-
CAPRISA eThekweni Clinical Research Site
Berea, 4001, South Africa
-
Centre for Lung Infection and Immunity UCT Lung Institute
Cape Town, 7700, South Africa
-
Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC) (recruiting participants for Part B only)
Maputo, 1102, Mozambique
-
Centro de Investigação em Saúde de Manhiça (CISM) (recruiting participants for Part B only)
Manhiça, 1929, Mozambique
-
Desmond Tutu Health Foundation - Masiphumele Research Office
Cape Town, 7975, South Africa
-
South African Tuberculosis Vaccine Initiative SATVI
Cape Town, 6850, South Africa
-
The Aurum Institute Tembisa CRC Clinic 4
Tembisa, 1632, South Africa